SBRT Appears Effective for Oligometastatic Prostate Cancer

Share this content:
Stereotactic body radiation therapy achieves good local control of metastases in patients with recurrent PCa following primary treatment, study finds. (Image courtesy of Fox Chase Cancer Center)
Stereotactic body radiation therapy achieves good local control of metastases in patients with recurrent PCa following primary treatment, study finds. (Image courtesy of Fox Chase Cancer Center)

Stereotactic body radiation therapy (SBRT) appears to be an effective treatment for oligometastatic disease in patients with recurrent prostate cancer (PCa), a new study suggests.

Ciro Franzese, MD, of Humanitas Clinical and Research Hospital, Milan-Rozzano, Italy, and colleagues analyzed findings from 64 patients who underwent SBRT for 90 metastases. Fifty patients (78.1%) received SBRT for lymph node metastases, 2 patients (3.1%) were treated simultaneously for lymph node and bone metastases, and 10 (15.7%) were treated for bone metastases only. Two patients received SBRT for lung metastases. Of the 64 patients, 27 were treated with androgen deprivation therapy (ADT) when they underwent SBRT and 37 were not.

The median follow-up was 15.2 months. Rates of local control at 6, 12, and 18 months were 94%, 88%, and 84%, respectively, the investigators reported in Cancer Medicine. Patients with castration-resistant disease had a significant 2-fold increased risk of disease progression than those with castration-sensitive disease. Oligoprogressive patients were less likely than oligorecurrent patients to achieve local control.

According to National Comprehensive Cancer Network criteria, 3.1%, 54.7%, and 42.2% had low-, intermediate-, and high-risk disease, respectively.

The study population, which had a median age of 71.8 years, included patients treated initially with radical surgery (20.3%), radical surgery plus adjuvant or salvage radiotherapy (54.7%), radical radiotherapy alone (7.8%), ADT (7.8%), and high intensity focused ultrasound (9.4%). The median time to biochemical relapse was 32.8 months.

Radiotherapy was delivered with a median dose of 42 Gy (range 18–60) in 2–8 fractions. The median dose per fraction was 7.5 Gy. Of the 64 patients, 19 (29.7%) had castration-resistant disease when undergoing SBRT.

Reference

  1. Franzese C, Zucali PA, Di Brina L, et al. The efficacy of stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer. Cancer Med. 2018; published online ahead of print. doi: 10.1002/cam4.1707.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs